drugset / Trial / NCT01516060
The Neurocognitive Sub-study of Encore1
Phase 3
Completed
71 enrolled
Kirby Institute
The HIV Netherlands Australia Thailand Research Collaboration · collab
RandomizedParallel-groupDouble-blindScreening
Summary
The purpose is to investigate whether HIV and HIV medication can affect certain areas of brain function. This study will look at possible changes in brain function including memory, concentration and thought processes to see if there are any differences between the two doses of efavirenz used in the Encore1 study and also the level of efavirenz in the blood
Timeline
- Start
- 2012-01
- Primary completion
- 2013-03
- Completion
- 2013-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efavirenz | Other / unclassified | 400 mg | — |
| Comparator | Efavirenz | Other / unclassified | 600 mg | — |